CoronaVac efficacy at 50-90% in Brazilian trials – Sao Paulo health secretary
- CoronaVac COVID-19 vaccine is developed by China's Sinovac Biotech Ltd
- Results of trials in Brazil are known exclusively by Sao Paulo state’s Butantan Institute
- At Sinovac’s request, Sao Paulo’s health department has not yet received the full trial results
China’s Sinovac Biotech Ltd developed CoronaVac COVID-19 vaccine showed efficacy between 50% and 90% in Brazilian trials, Sao Paulo state health secretary said, Reuters reported.
Results of trials in Brazil are known exclusively by Sao Paulo state’s Butantan Institute biomedical research centre, which has an agreement with Sinovac to produce the vaccine, said health secretary Jean Gorinchteyn.
While the full trial results will be released on January 7, first trials showed efficacy above 50%, the minimum required by Brazilian health regulator Anvisa, and below 90%, Gorinchteyn said in an interview with CBN radio aired late on Thursday.
At Sinovac’s request, Sao Paulo’s health department has not yet received the full trial results, he said, adding that the company will review the data before announcing final results.
Gorinchteyn said on Friday in a televised interview with the GlowboNews channel that Butantan will disclose the data trial results on Jan. 7.
Also read: Jair Bolsonaro’s Brazil vaccination plan faces scathing criticism
Brazil has registered 7,448,560 confirmed coronavirus cases and 190,488 deaths from COVID-19, the country’s health ministry said on Friday.
Related Articles
ADVERTISEMENT